Blood-product usage in cardiac surgery.

Area of Science:

• Cardiovascular Surgery
• Hematology
• Anesthesiology

Background:

• Patients undergoing cardiac surgery frequently present with pre-existing congenital or acquired coagulation disorders.
• Cardiopulmonary bypass (CPB) is known to induce coagulopathies affecting plasma proteins, platelets, and fibrinolysis.
• These CPB-induced abnormalities may not always lead to clinically significant bleeding.

Purpose of the Study:

• To review the management of coagulation defects in cardiac surgery patients.
• To discuss the hemostatic challenges induced by cardiopulmonary bypass.
• To explore current and future therapeutic strategies for bleeding in this population.

Main Methods:

• Literature review of coagulation abnormalities in cardiac surgery.
• Analysis of laboratory assessment and blood-component usage for bleeding management.
• Evaluation of synthetic alternatives and pharmacologic agents like DDAVP and aprotinin.

Main Results:

• Preoperative identification and correction of coagulation defects are crucial.
• CPB-induced coagulopathies can typically be managed with appropriate laboratory assessment and blood products.
• Blood product transfusion carries inherent risks, driving interest in synthetic alternatives.

Conclusions:

• While CPB-induced bleeding can usually be managed, risks associated with blood products necessitate safer alternatives.
• DDAVP and aprotinin show promise but require further investigation regarding efficacy and thrombotic risks.
• Future advancements aim for safer and more effective bleeding therapies in cardiac surgical patients.